文献速递乳腺癌支持与姑息治疗

心脏肿瘤学研究中新疗法的多学科方法(MANTICORE 101-乳腺):预防曲妥珠单抗相关心脏毒性的随机试验

Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
PubMed 文献 · J Clin Oncol · 2016-11-28

本研究为双盲、安慰剂对照试验,HER2阳性早期乳腺癌患者随机接受培哚普利、比索洛尔或安慰剂(1:1:1),与曲妥珠单抗辅助治疗同期使用。曲妥珠单抗17周期后,培哚普利组、比索洛尔组与安慰剂组的左心室舒张末期容积指数变化无显著差异(P=.36);比索洛尔组左心室射血分数下降较培哚普利组和安慰剂组减轻(P=.001)。结论:两种药物耐受性良好,可减轻左心室射血分数下降,但未预防曲妥珠单抗介导的左心室重构这一主要终点。

要点

  • 培哚普利、比索洛尔与安慰剂三组的左心室舒张末期容积指数变化无显著差异(P=.36)。
  • 比索洛尔组左心室射血分数下降较培哚普利组和安慰剂组减轻(P=.001)。
  • 培哚普利和比索洛尔用药是多变量分析中维持左心室射血分数的独立预测因素。

核心结论

  • 培哚普利和比索洛尔在接受曲妥珠单抗的HER2阳性早期乳腺癌患者中耐受性良好,并保护患者免受癌症治疗相关的左心室射血分数下降;但这两种药物未能预防曲妥珠单抗介导的左心室重构这一主要终点。

研究设计与样本

  • 双盲、安慰剂对照试验,HER2阳性早期乳腺癌患者随机(1:1:1)接受培哚普利、比索洛尔或安慰剂,持续整个曲妥珠单抗辅助治疗期间。
  • 基线及第17周期后行心脏磁共振成像测定左心室容积和左心室射血分数。
  • 培哚普利组33例,比索洛尔组31例,安慰剂组30例;各组基线人口学、肿瘤及心血管特征相似。

主要发现

  • 曲妥珠单抗17周期后,左心室舒张末期容积指数在培哚普利组增加(+7 ± 14 mL/m2)、比索洛尔组增加(+8 mL ± 9 mL/m2)、安慰剂组增加(+4 ± 11 mL/m2;P = .36)。
  • 次要分析中,曲妥珠单抗介导的左心室射血分数下降在比索洛尔组(-1 ± 5%)较培哚普利组(-3 ± 4%)和安慰剂组(-5 ± 5%)减轻(P = .001)。
  • 多变量分析显示,培哚普利和比索洛尔使用是维持左心室射血分数的独立预测因素。
  • 研究药物耐受性良好,无严重不良事件。

关键数值与推荐

  • 主要终点为左心室舒张末期容积指数变化,三组间无显著差异(P = .36)。
  • 左心室射血分数变化的组间比较P = .001,比索洛尔组下降幅度小于培哚普利组和安慰剂组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive) breast cancer is dose-independent cardiac dysfunction. Angiotensin-converting enzyme inhibitors and β-blockers are recommended first-line agents for heart failure. We hypothesized that angiotensin-converting enzyme inhibitors and β-blockers could prevent trastuzumab-related cardiotoxicity. Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant therapy. Patients underwent cardiac magnetic resonance imaging at baseline and post-cycle 17 for the determination of left ventricular volumes and left ventricular ejection fraction (LVEF). Cardiotoxicity was evaluated as the change in indexed left ventricular end diastolic volume and LVEF. Results Thirty-three patients received perindopril, 31 received bisoprolol, and 30 received placebo. Baseline demographic, cancer, and cardiovascular profiles were similar between groups. Study drugs were well tolerated with no serious adverse events. After 17 cycles of trastuzumab, indexed left ventricular end diastolic volume increased in patients treated with perindopril (+7 ± 14 mL/m2), bisoprolol (+8 mL ± 9 mL/m2), and placebo (+4 ± 11 mL/m2; P = .36). In secondary analyses, trastuzumab-mediated decline in LVEF was attenuated in bisoprolol-treated patients (-1 ± 5%) relative to the perindopril (-3 ± 4%) and placebo (-5 ± 5%) groups ( P = .001). Perindopril and bisoprolol use were independent predictors of maintained LVEF on multivariable analysis. Conclusion Perindopril and bisoprolol were well tolerated in patients with HER2-positive early breast cancer who received trastuzumab and protected against cancer therapy-related declines in LVEF; however, trastuzumab-mediated left ventricular remodeling-the primary outcome-was not prevented by these pharmacotherapies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2016. PMID: 27893331. doi:10.1200/JCO.2016.68.7830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。